Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.63 |
| ▸ | RXRA | P19793 | 5/20 | 0.63 |
| ▸ | RARA | P10276 | 4/20 | 0.63 |
| ▸ | RARB | P10826 | 4/20 | 0.63 |
| ▸ | RARG | P13631 | 4/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.63 |
| ▸ | APP | P05067 | 4/20 | 0.63 |
| ▸ | SNCA | P37840 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.63 |
| ▸ | RXRB | P28702 | 2/20 | 0.63 |
| ▸ | RXRG | P48443 | 2/20 | 0.63 |
| ▸ | RORC | P51449 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006702 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL1895263 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2008326 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL57568 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL3422972 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL4399478 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2011547 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2005744 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2005804 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2008700 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0415766-B1 | Use of retinoids for reversing glucocorticoid-induced skin atrophy | ORTHO PHARMA CORP (US) | 1997-01-08 | — | — | EP | claimed |
| US-5431925-A | Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression | SNOW BRAND MILK PRODUCTS CO., LTD. (JP) | 1995-07-11 | — | — | US | claimed |
| EP-0625045-A4 | METHODS OF TREATING INFLAMMATORY DERMATOSES. | KLIGMAN ALBERT M (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0625045-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | Kligman, Albert M. (US) | 1994-11-23 | — | — | EP | claimed |
| WO-1993015740-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | KLIGMAN ALBERT M (US) | 1993-08-19 | — | — | WO | claimed |
| US-5019569-A | Topical Administritation of Retinoids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-05-28 | — | — | US | claimed |
| EP-0415766-A2 | Use of retinoids for reversing glucocorticoid-induced skin atrophy | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| CN-111334537-A | Method for synthesizing enzyme-catalyzed dabigatran etexilate intermediate | 中山万汉制药有限公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-2397120-B2 | Fragrance-containing core shell microcapsules | TAKASAGO PERFUMERY CO LTD (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-9464263-B2 | Core shell microcapsules and liquid consumer product | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-10-11 | — | — | US | disclosed |
| EP-2397120-B1 | Fragrance-containing core shell microcapsules | TAKASAGO PERFUMERY CO LTD (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-20130164355-A1 | CORE SHELL MICROCAPSULES AND LIQUID CONSUMER PRODUCT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| CN-102946843-A | Core-shell microcapsules and liquid commodity | TAKASAGO PERFUMERY CO LTD | 2013-02-27 | — | — | CN | disclosed |
| EP-1200058-B1 | SKIN CARE COMPOSITION CONTAINING PETROSELINIC ACID | UNILEVER PLC (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6440434-B1 | PETROSELINIC ACID OR DERIVATIVE; AND RETINOL, RETINOIC ACID OR RETINYL LINOLEATE; TOPICAL; SKIN AGING AND WRINKLE RESISTANCE; DERMATOLOGY | CONOPCO, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1200058-A1 | SKIN CARE COMPOSITION CONTAINING PETROSELINIC ACID | UNILEVER PLC (GB) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001008649-A1 | SKIN CARE COMPOSITION CONTAINING PETROSELINIC ACID | UNILEVER PLC (GB) | 2001-02-08 | — | — | WO | disclosed |
| EP-0415766-A2 | Use of retinoids for reversing glucocorticoid-induced skin atrophy | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032751-A1 | Methods for treatment of dermatological conditions | KRT18, CUTA, TUBB1 | ALDH1A1 458/4885ADORA3 4235/4885MAPT 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.